June 14, 2022 8:04am

What do you do in this sector, pick your targets, de-risk, de-gross, hide the portfolio in draw, or just stay in the game – there is STILL value out-there but,appreciation willnot be acclaimed in one (1) session!

Pre-open indications: 6 Positive Indication, 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP+0.14% (+43 points), S&P futures are UP +0.24% (+9 points) and NASDAQ futures are UP +0.45% (+51 points) early in the pre-open – so far,


U.S. stock futures rose Tuesday

European stocks were fluctuating having started their session up 1%

Asia-Pacific stockd were mostly lower



Traders are awaiting a monetary policy announcement from the Fed later in the week.

The Nasdaq suffered its fourth (4th) straight drop and has declined roughly 30% this year.

The CBOE Volatility Index or VIX - fear gauge' surged to one-month high of 34.02 and could mean more selling pressure is in store.

Economic Data Docket: more inflation data is due out with the Labor Department's producer price index Tuesday, while the Fed's highly-anticipated two-day meeting will also kick off.

·         Producer prices are expected to rise 0.8% in May after moving up 0.5% in April, according to Econoday. Producer inflation is expected to jump 11% year-over-year. The producer price index is a measure of pricing strength based on selling prices received by domestic producers for their output.


RegMed Investors’ (RMi) closing bell: “shaken, rattled and then rolled with no place to hide. Bottom, bottom; who can even envision the next bottom as the cell and gene therapy equities melt-down, also waiting for the Fed meeting this week” … https://www.regmedinvestors.com/articles/12471

Ebb and flow –

Q2/22 –

June – 4 positive and 5 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive Upside Indications:

Caribou Biosciences (CRBU) closed down-$1.84 to $5.10 <52-week low of $5.02> with a positive +$0.30 or +5.88%. However, according to TheStreet “Shares of the gene-editing pioneer cratered 20% following the latest data readout from its lead drug candidate CB-010. The experimental asset is a CAR-T cell therapy engineered to improve antitumor activity. On the one hand, all patients who received the CRISPR gene-edited cells entered remission initially. On the other hand, most had their cancer return after only six months”.

Beam Therapeutics (BEAM) closed down -$3.22 to $29.86 <52-week low of $27.77> after Friday’s -$3.71 to $33.08 with a positive +$1.54 or +5.16% pre-open indication.

CRISPR Therapeutics (CRSP) closed down -$8.49 to $55.27 after Friday’s -$7.94 <52-week low of $42.51> with a positive +$0.33 or +0.60% pre-open indication,

Fate Therapeutics (FATE) closed down -$2.03 to $17.78 after Friday’s -$3.67 <52-week low of $17.11> with a positive +$0.12 or +0.67% pre-open indication,

Sage Therapeutics (SAGE) closed down -$2.58 to $32.00 ,52-week low of $27.36> with a positive +$1.57 or +4.91% pre-open indication.

Intellia Therapeutics (NTLA) closed down -$3.49 to $38.96 after Friday’s -$7.69 <52-week low of $38.05> with a positive +1.02 or +2.62% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed up +$ 0.15 with 100 shares traded after Friday’s +$0.065 with 295 shares traded on Friday, Thursday’s $0.00 with 43 shares traded, Wednesday with 2 shares traded, and last Tuesday’s $0.00 at $4.68 with 65 shares traded.

WARNING:  Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors. Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing.

Harvard BIOSCIENCE  (HBIO) and BSTG filed a new 8-K in lieu of cash payment < https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=116769338&type=HTML&formType=8-K&dateFiled=2022-06-13&cik=0001563665&CK=1563665&symbol=0001563665&companyName=Biostage >

BSTG seems to always finagle a finagle and NOTHING is CLEAN and STRAIGHTFORWARD.

  •  is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?
  • So, Has BSTG filed its Annual Report to the FDA, isn’t it a “Material Fact”?
  • Is yet ANOTHER financing on-going of 5+M shares being prepared to be sold?


The BOTTOM LINE: The cell and gene therapy suffered significant losses Thursday, Friday and Monday, with the major indexes undercutting key short-term support. Surrounding the sector’s coverage group, decliners trounced winners.

I wonder if algorithms will recognize the "rules" in our favor!

The market action, especially in cell and gene therapy stocks, has been weak and opened foe slow and mild appreciation.

We are left with choosing to hang on to decliners for another session down the road. But given the sector shifts and the fierce, sudden sell-offs, investors may want to at least consider taking partial profits – when they can.

The stock market rally had its worst day in weeks. The major indexes closed below their 21-day moving averages for the first time since late May and undercut their June intraday lows. <IBD>

I STILL haven’t heard the bugle sound of a sustainable advance or rally … rising rates and slowing economic growth are not a supportive environment for investors.

Again, as have I written (repeatedly), “There's a battle in the cell and gene therapy sector between which or what breaks first: share pricing resistance or tumbling into yet another downturn as fear remains beneath the strength of any positive close” …

This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.

I have NOT seen ANY step-up of declining company investments by ANY CEOs and their management teams – WHY NOT?

I try to keep it simple … and short!

There is VALUE out there however, it’s about playing or betting the timing of the sector.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.